Bis­pecifics con­tin­ue im­pres­sive ef­fi­ca­cy streak, but com­pa­nies look to re­duce side ef­fects: #ASH23

SAN DIEGO — Bis­pe­cif­ic an­ti­bod­ies from Re­gen­eron, John­son & John­son, Ab­b­Vie and Roche con­tin­ue to show im­pres­sive ef­fi­ca­cy in lym­phomas and myelo­ma based on new tri­al da­ta pre­sent­ed at the Amer­i­can So­ci­ety of Hema­tol­ogy’s an­nu­al meet­ing.

How­ev­er, for some agents, tox­i­c­i­ties like cy­tokine re­lease syn­drome re­main a sub­stan­tial con­cern and the FDA on Mon­day held a joint ses­sion at ASH to dis­cuss the bal­ance of ef­fi­ca­cy and safe­ty for some of the re­cent­ly ap­proved bis­pecifics that come with boxed safe­ty warn­ings.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER